NOVEL ANTIANDROGEN ARN-509 IN HIGH-RISK NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER

被引：0
|
作者：
Shore, Neal D.
Antonarakis, Emmanuel S.
Ryan, Charles J.
Berry, William R.
Liu, Glenn
Higano, Celestia
Maneval, Edna Chow
Bandekar, Rajesh
de Boer, Carla J.
Todd, Mary B.
Yu, Margaret K.
Rathkopf, Dana E.
Smith, Matthew R.
机构：
来源：
JOURNAL OF UROLOGY | 2015年 / 193卷 / 04期
关键词：
D O I：
10.1016/j.juro.2015.02.1961
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP87-16
引用
收藏
页码：E1090 / E1090
页数：1
相关论文
共 50 条
  • [41] FDA Approves Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (09) : 498 - 498
  • [42] Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
    Figueiredo, Arnaldo
    Costa, Luis
    Mauricio, Maria Joaquina
    Figueira, Luis
    Ramos, Rodrigo
    Martins-da-Silva, Carlos
    CLINICAL DRUG INVESTIGATION, 2022, 42 (08) : 631 - 642
  • [43] Re: Enzalutamide and Survival in Nonmetastatic Castration-Resistant Prostate Cancer
    Mori, Keiichiro
    Egawa, Shin
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY, 2021, 79 (03) : 430 - 431
  • [44] Re: Enzalutamide in Men with Nonmetastatic, Castration-resistant Prostate Cancer
    Mason, Malcolm
    EUROPEAN UROLOGY, 2018, 74 (06) : 845 - 845
  • [45] Re: Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2021, 205 (04): : 1226 - 1227
  • [46] Recent Updates in the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
    Berger, Aaron
    ONCOLOGY-NEW YORK, 2021, 35 (12): : 846 - 848
  • [47] Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
    Schultz, Neil M.
    O'Day, Ken
    Sugarman, Rebecca
    Ramaswamy, Krishnan
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (04): : 538 - 549
  • [48] ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer.
    Fizazi, Karim
    Shore, Neal D.
    Tammela, Teuvo L. J.
    Sarapohja, Toni
    Vuorela, Annamari
    Kuss, Iris
    Snapir, Amir
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] DISEASE SPECIFIC COST ANALYSIS OF THE NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER HEALTH STATES
    Yanev, I
    Aprikian, A.
    Nablsi, E.
    Primiani, J.
    Vaillancourt, Z.
    Dragomir, A.
    VALUE IN HEALTH, 2018, 21 : S73 - S73
  • [50] ARN-509 Androgen receptor signaling inhibitor Prostate cancer therapy
    Reviriego, C.
    DRUGS OF THE FUTURE, 2015, 40 (02) : 101 - 108
12345